MedTrace Logo

Effect of Reslizumab in Chronic Rhinosinusitis

NCT02799446 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2018-02-01

No results posted yet for this study

Summary

The purpose of this study is to determine whether Reslizumab is effective for the treatment of chronic sinusitis.

Conditions

  • Sinusitis

Interventions

DRUG

Reslizumab

Reslizumab 3mg/kg intravenous (IV)

DRUG

Placebo

Matching Placebo intravenous (IV)

Sponsors & Collaborators

  • Joshua S. Jacobs

    lead OTHER

Principal Investigators

  • Joshua Jacobs, MD · Allergy and Asthma Clinical Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-30
Primary Completion
2019-07-31
Completion
2019-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02799446 on ClinicalTrials.gov